Eliem Therapeutics (NASDAQ:ELYM) Trading Down 2.5% - Here's What Happened

Key Points

• Eliem Therapeutics shares fell 2.5% to about $9.26 intraday (low $9.12) on a volume surge to 2,689,696 shares, a 453% increase versus average trading volume.
• The stock is trading above its 50‑day ($7.38) and 200‑day ($4.72) moving averages, has a market cap of $275.5 million and a negative P/E (−17.47), indicating the company is currently unprofitable.
• Eliem is a clinical-stage biotech focused on CNS therapies, with lead program ELI‑200 being developed for spasticity and neuropathic pain associated with spinal cord injury.

Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report)'s stock price fell 2.5% during trading on Wednesday . The company traded as low as $9.1201 and last traded at $9.26. 2,689,696 shares were traded during mid-day trading, an increase of 453% from the average session volume of 486,688 shares. The stock had previously closed at $9.50.

Eliem Therapeutics Price Performance

The firm's fifty day moving average price is $7.38 and its two-hundred day moving average price is $4.72. The stock has a market cap of $275.50 million, a price-to-earnings ratio of -17.47 and a beta of -0.39.

About Eliem Therapeutics

Eliem Therapeutics, Inc is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company's scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.

The company's most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.